Phase II proof concept study of RLM023 for Acne-vulgaris.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2018
Price : $35 *
At a glance
- Drugs Hypochlorous acid (Primary)
- Indications Acne vulgaris
- Focus Proof of concept; Therapeutic Use
- 17 Jul 2018 According to a Realm Therapeutics media release, the company has discontinued all programs which were based on Company's proprietary technology including RLM-023, after the PR-022 Atopic Dermatitis study results did not meet the company's threshold for continued investment.
- 15 Mar 2018 New trial record
- 12 Mar 2018 According to a Realm Therapeutics media release, company intends to file an Investigational New Drug (IND) application in early Q4 2018.